{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"MRD-negative CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"sCR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"MR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"DP"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"BOR consisted of MRD-negative CR, sCR, CR, VGPR, PR, MR, SD \\& PD per 2016 IMWG. MRD: evaluated using adaptive NGS for MRD assay \\& carried out on relevant specimen to understand activity of SEA-BCMA. sCR: CR \\& normal FLC ratio \\& absence of clonal cells in bone marrow by IC/ IF. CR: Negative immunofixation of serum \\& urine disappearance of any STP, \\& \\<5% plasma cells in bone marrow. VGPR: SMP \\& UMP detectable by IF but not on electrophoresis/ \\>= 90% reduction(R) in SMP level+UMP level \\<100 mg/24 hr, PR: \\>=50% R of SMP \\& R in 24-hr UMP by \\>=90%/by \\<200 mg/24 hr. If SMP \\& UMP are unmeasurable, \\>=50% decrease in difference between involved \\& uninvolved FLC levels were required in place of M-protein criteria. SD: Not meeting criteria for CR, VGPR, PR, MR, or progression. MR: 25-49% R of SMP \\& R in 24-hr UMP by 50-89%, which still exceeds 200mg/24 hr. DP: objective evidence of tumor progression(based on serum/urine/BM assessments) \\&/clinical progression/investigator.","groups":[{"description":"Participants received SEA-BCMA 1600 mg as an IV infusion q1wk as induction dose for the first two cycles, followed by q2wk as maintenance dose in subsequent cycles, of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG000","title":"Part B: SEA-BCMA 1600mg"}],"paramType":"NUMBER","populationDescription":"All treated participants analysis set included all treated participants who received any amount of SEA-BCMA.","reportingStatus":"POSTED","timeFrame":"From the first dose of study treatment until the first documented sCR or CR or PR or VGPR or new anti-cancer therapies or death, whichever occurred first (maximum up to 34 months)","title":"Percentage of Participants With BOR as Per the IMWG Uniform Response Criteria: Part B","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}